Charles River/$CRL
1D1W1MYTD1Y5YMAX
Capital at risk
About Charles River
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
- Ticker
- $CRL
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 19,000
- Headquarters
- Wilmington, United States
- Website
- www.criver.com
Charles River Metrics
BasicAdvanced
$13B
-
-$4.88
1.38
-
Price and volume
Market cap
$13B
Beta
1.38
52-week high
$303.31
52-week low
$144.26
Average daily volume
939K
Financial strength
Current ratio
1.348
Quick ratio
0.796
Long term debt to equity
1.048
Total debt to equity
1.05
Interest coverage (TTM)
5.29%
Profitability
EBITDA (TTM)
849.118
Gross margin (TTM)
34.59%
Net profit margin (TTM)
-5.96%
Operating margin (TTM)
14.06%
Effective tax rate (TTM)
-28.65%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
4.11%
Return on equity (TTM)
-7.52%
Valuation
Price to revenue (TTM)
3.333
Price to book
4.59
Price to tangible book (TTM)
-26.56
Price to free cash flow (TTM)
35.969
Free cash flow yield (TTM)
2.78%
Free cash flow per share (TTM)
7.587
Growth
Revenue change (TTM)
-0.74%
Earnings per share change (TTM)
255.12%
3-year revenue growth (CAGR)
-1.45%
10-year revenue growth (CAGR)
10.36%
3-year earnings per share growth (CAGR)
-19.73%
10-year earnings per share growth (CAGR)
5.13%
What the Analysts think about Charles River
Analyst ratings (Buy, Hold, Sell) for Charles River stock.
Analyst projections of the future price of Charles River stock.
Bulls say / Bears say
Contract drug developer CRL raised its 2026 adjusted EPS guidance to $11.15–$11.45 after Q2 results beat estimates, driven by improving DSA and Manufacturing performance (Reuters)
The DSA segment delivered organic revenue growth of 0.2% year-over-year to $606.5 million in Q2 2026—the first organic uptick since Q3 2023, underscoring stabilization in safety assessment demand (Reuters)
Acquisition of PathoQuest SAS strengthens Charles River’s biologics testing capabilities by adding advanced in vitro NGS-based safety assessment methods, expanding its non-animal testing portfolio (Reuters)
Organic revenue declined 1.5% in Q1 2026 as RMS revenue fell 2.2% and DSA revenue slipped 1.4% on an organic basis, reflecting soft demand in core preclinical services (SEC)
Including the impact of planned divestitures, 2026 guidance calls for organic revenue contraction of 0.5%–1.5%, highlighting headwinds from strategic asset sales and FX pressures (SEC)
RMS segment outlook forecasts NHP revenue below 2025 levels (≈200 bps headwind) and continued CRADL™ occupancy constraints, indicating persistent drag on research models growth (Charles River Investor Presentation)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
Charles River Financial Performance
Revenues and expenses
Charles River Earnings Performance
Company profitability
Upcoming events
No upcoming events
Charles River News
AllArticlesVideos
Funds containing Charles River
AllUSDEURGBP
Fund name | Fund size | $CRL weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.38% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.38% |
iShares Healthcare Innovation£DRDR | £1B | 1.38% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.29% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.29% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.